Patricia Van Arnum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Patricia Van Arnum


Patricia Van Arnum Pharmtech editor

Patricia Van Arnum
Executive Editor
732.346.3072, pvanarnum@advanstar.com

Patricia Van Arnum, executive editor, covers active pharmaceutical ingredients (APIs), intermediates, fine chemicals, advances in process R&D, formulation development, and finished drug-product manufacturing for Pharmaceutical Technology. She also is editor of Sourcing and Management, a monthly newsletter of Pharmaceutical Technology covering sourcing, the pharmaceutical supply-chain, API synthesis and manufacturing, and formulation development and finished drug-product manufacturing. Patricia has 20 years of experience as a business and science journalist and editor, which includes 17 years of experience covering the pharmaceutical and fine-chemicals industries. Patricia was formerly executive editor of Chemical Market Reporter (now ICIS Chemical Business) and was with CMR and ICIS from 1995–2005. She joined Pharmaceutical Technology as a senior editor in January 2006. She holds undergraduate degrees in chemistry, economics, and political science. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, the American Medical Writers Association, and the American Association for the Advancement of Science.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here